Related references
Note: Only part of the references are listed.Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
Sarah Gooding et al.
BLOOD (2021)
CUL4A regulates endometrial cancer cell proliferation, invasion and migration by interacting with CSN6
Xiangrong Wang et al.
MOLECULAR MEDICINE REPORTS (2021)
IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma
Santiago Barrio et al.
HAEMATOLOGICA (2020)
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
Nadine Abdallah et al.
BLOOD CANCER JOURNAL (2020)
Exploiting DNA repair defects in triple negative breast cancer to improve cell killing
Kevin J. Lee et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma
Ting Li et al.
CANCER BIOLOGY & MEDICINE (2020)
Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma
Konstantinos Dimopoulos et al.
LEUKEMIA & LYMPHOMA (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance
Yiyin Zhang et al.
CANCERS (2019)
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
Laurens E. Franssen et al.
HAEMATOLOGICA (2018)
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
Laurens E. Franssen et al.
HAEMATOLOGICA (2018)
CUL4A as a marker and potential therapeutic target in multiple myeloma
Yougang Yang et al.
TUMOR BIOLOGY (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma
Shahzad Raza et al.
CURRENT CANCER DRUG TARGETS (2017)
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
K. Martin Kortum et al.
BLOOD (2016)
High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
Maryam Pourabdollah et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Georg Petzold et al.
NATURE (2016)
Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
C. C. Bjorklund et al.
BLOOD CANCER JOURNAL (2015)
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
Shang-Yi Huang et al.
ANNALS OF HEMATOLOGY (2014)
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Yuan Xiao Zhu et al.
BLOOD (2014)
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in Multiple myeloma patients?
Ahmed M. L. Bedewy et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
The clinical significance of cereblon expression in multiple myeloma
Steven R. Schuster et al.
LEUKEMIA RESEARCH (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
Annemiek Broyl et al.
BLOOD (2013)
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
Daniel Heintel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer
Shancheng Ren et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2012)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
The Molecular Basis of CRL4DDB2/CSA Ubiquitin Ligase Architecture, Targeting, and Activation
Eric S. Fischer et al.
CELL (2011)
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3+ regulatory T cells
Roopali Gandhi et al.
NATURE IMMUNOLOGY (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Ikaros controls isotype selection during immunoglobulin class switch recombination
MacLean Sellars et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity
M Cortés et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Share Paper
